Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 67,279 shares, a growth of 1,315.5% from the June 15th total of 4,753 shares. Based on an average daily volume of 201,808 shares, the days-to-cover ratio is presently 0.3 days. Currently, 4.0% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Bone Biologics Price Performance

Shares of NASDAQ:BBLG traded up $0.01 during trading on Friday, reaching $1.39. 24,135 shares of the company’s stock traded hands, compared to its average volume of 143,856. Bone Biologics has a 12 month low of $1.05 and a 12 month high of $4.13. The company has a 50 day moving average of $1.32 and a 200-day moving average of $1.37. The stock has a market capitalization of $2.50 million, a P/E ratio of -0.61 and a beta of 0.90.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). Equities research analysts predict that Bone Biologics will post -1.17 earnings per share for the current fiscal year.

Institutional Trading of Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC lifted its holdings in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the period. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. 34.30% of the stock is owned by institutional investors.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.